Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1) Peptid

AKT1 Wirt: Synthetic Sodium azide
Rockland
Produktnummer ABIN964063
Hersteller Produkt- Nr.: 000-000-401
  • Target Alle AKT1 Produkte
    AKT1 (V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1))
    Protein-Typ
    Synthetic
    Quelle
    • 26
    Synthetic
    Hersteller Produkt- Nr.
    000-000-401
    Hersteller
    Rockland
    Verwendungszweck
    AKT Peptide
    Produktmerkmale
    control peptide, blocking peptide, RAC-PK-alpha, Protein kinase B, PKB, C-AKT, RAC-alpha serine/threonine-protein kinase, Proto-oncogene c-Akt, AKT1, AKT Serine/Threonine Kinase 1, AKT 1 Antibody, AKT-1.
    Reinheit
    Greater than 95% specific peptide
    Sterilität
    Sterile filtered
  • Applikationshinweise
    Optional[Flow Cytometry Dilution]: Akt blocking peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1.0 mg/mL
    Buffer

    Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

    Stabilizer: None

    Preservative: 0.01 % (w/v) Sodium Azide
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
    Haltbarkeit
    6 months
  • Target
    AKT1 (V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1))
    Hintergrund
    Background: Non-specific binding of an antibody to proteins other than the antigen can sometimes occur. This is usually more common with polyclonal antibodies, but can also occur with monoclonals as well. To determine which band or staining is specific, the AKT immunizing peptide blocking experiment can be performed. Prior to the staining protocol, the anti-AKT antibody is neutralized (incubated with an excess of peptide that corresponds to the epitope recognized by the antibody). The AKT antibody that is bound to the blocking peptide is no longer available to bind to the epitope present in the protein on the Western blot or in the cell. The neutralized antibody is then used side-by-side with the antibody alone, and the results are compared. By comparing the staining from the blocked antibody versus the antibody alone, you can see which staining is specific: this staining will be absent from the Western blot or immunostaining performed with the neutralized antibody.
Sie sind hier:
Kundenservice